London, UK and Montreal, Canada, November 8, 2017 (Newswire) –Fortuna Fix (“Fortuna”), a private, clinical-stage Regenerative Medicine company is aiming to be the first to bring to the clinic a patient’s own neural stem cells (autologous) produced by direct reprogramming (“drNPCs”
[Read more…]
Genetically Modified Muscle Progenitor Cells with Stem Cell Medicine Ltd.
In the world of stem cells, there are a number of well-recognized market participants that receive a great deal of attention from the stem cell community.
At the same time, there are brilliant companies that quietly operate under the radar screen, building themselves up one intelligent and methodical step at a time. [Read more…]
Meet the New York Scientist Using Stem Cells as a Treatment For MS
Treatment for multiple sclerosis (MS) is an evolving area and one in which new therapeutic approaches are rapidly advancing. Led by Dr. Saud Sadiq, the Tisch MS Research Center of New York is pursuing a Phase II clinical trial exploring the use of stem cell technology for the treatment for MS. The announcement followed positive results from an FDA-approved Phase I stem cell trial for MS. [Read more…]
Breakthrough Regenerative Therapeutics Company Establishes Scientific Advisory Board
Montreal, Canada, May 4, 2017 – Fortuna Fix Inc., (“Fortuna”), a private, clinical-stage biotech company is aiming to be the first to eliminate the need for embryonic and fetal stem cells by using direct reprogramming of autologous cells to treat neurodegenerative diseases. Fortuna announced today the launch of its Scientific Advisory Board (“SAB”) with Professor Michael Fehlings, MD, PhD, Father Kevin FitzGerald, S.J., PhD, COL (R) Dallas Hack, MD, MPH, and Professor James Giordano, PhD. [Read more…]
Stem Cell Research Products | Market Size, Segments, & Trends
“Stem Cell Research Products – Opportunities, Tools, & Technologies” is a global strategic report that evaluates opportunities across the entire stem cell product spectrum with an emphasis on opportunities for research product development.
Stem Cells Size | A Stem Cell Business Opportunity
In this article:
